HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
Humans
Oligodendroglioma
/ diagnosis
Isocitrate Dehydrogenase
/ genetics
Immunohistochemistry
Vimentin
/ metabolism
Brain Neoplasms
/ genetics
Proteomics
Mutation
Glioma
/ genetics
Astrocytoma
/ genetics
Chromosomes, Human, Pair 1
/ genetics
Chromosomes, Human, Pair 19
/ genetics
Microfilament Proteins
/ metabolism
Adaptor Proteins, Signal Transducing
/ metabolism
1p/19q
ATRX
HIP1R
IDH
Vimentin
proteomics
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
pubmed:
6
5
2022
medline:
3
12
2022
entrez:
5
5
2022
Statut:
ppublish
Résumé
IDH-mutant gliomas are separate based on the codeletion of the chromosomal arms 1p and 19q into oligodendrogliomas IDH-mutant 1p/19q-codeleted and astrocytomas IDH-mutant. While nuclear loss of ATRX expression excludes 1p/19q codeletion, its limited sensitivity prohibits to conclude on 1p/19q status in tumors with retained nuclear ATRX expression. Employing mass spectrometry based proteomic analysis in a discovery series containing 35 fresh frozen and 72 formalin fixed and paraffin embedded tumors with established IDH and 1p/19q status, potential biomarkers were discovered. Subsequent validation immunohistochemistry was conducted on two independent series (together 77 oligodendrogliomas IDH-mutant 1p/19q-codeleted and 92 astrocytomas IDH-mutant). We detected highly specific protein patterns distinguishing oligodendroglioma and astrocytoma. In these patterns, high HIP1R and low vimentin levels were observed in oligodendroglioma while low HIP1R and high vimentin levels occurred in astrocytoma. Immunohistochemistry for HIP1R and vimentin expression in 35 cases from the FFPE discovery series confirmed these findings. Blinded evaluation of the validation cohorts predicted the 1p/19q status with a positive and negative predictive value as well as an accuracy of 100% in the first cohort and with a positive predictive value of 83%; negative predictive value of 100% and an accuracy of 92% in the second cohort. Nuclear ATRX loss as marker for astrocytoma increased the sensitivity to 96% and the specificity to 100%. We demonstrate that immunohistochemistry for HIP1R, vimentin, and ATRX predict 1p/19q status with 100% specificity and 95% sensitivity and therefore, constitutes a simple and inexpensive approach to the classification of IDH-mutant glioma.
Sections du résumé
BACKGROUND
IDH-mutant gliomas are separate based on the codeletion of the chromosomal arms 1p and 19q into oligodendrogliomas IDH-mutant 1p/19q-codeleted and astrocytomas IDH-mutant. While nuclear loss of ATRX expression excludes 1p/19q codeletion, its limited sensitivity prohibits to conclude on 1p/19q status in tumors with retained nuclear ATRX expression.
METHODS
Employing mass spectrometry based proteomic analysis in a discovery series containing 35 fresh frozen and 72 formalin fixed and paraffin embedded tumors with established IDH and 1p/19q status, potential biomarkers were discovered. Subsequent validation immunohistochemistry was conducted on two independent series (together 77 oligodendrogliomas IDH-mutant 1p/19q-codeleted and 92 astrocytomas IDH-mutant).
RESULTS
We detected highly specific protein patterns distinguishing oligodendroglioma and astrocytoma. In these patterns, high HIP1R and low vimentin levels were observed in oligodendroglioma while low HIP1R and high vimentin levels occurred in astrocytoma. Immunohistochemistry for HIP1R and vimentin expression in 35 cases from the FFPE discovery series confirmed these findings. Blinded evaluation of the validation cohorts predicted the 1p/19q status with a positive and negative predictive value as well as an accuracy of 100% in the first cohort and with a positive predictive value of 83%; negative predictive value of 100% and an accuracy of 92% in the second cohort. Nuclear ATRX loss as marker for astrocytoma increased the sensitivity to 96% and the specificity to 100%.
CONCLUSIONS
We demonstrate that immunohistochemistry for HIP1R, vimentin, and ATRX predict 1p/19q status with 100% specificity and 95% sensitivity and therefore, constitutes a simple and inexpensive approach to the classification of IDH-mutant glioma.
Identifiants
pubmed: 35511748
pii: 6578556
doi: 10.1093/neuonc/noac111
pmc: PMC9713528
doi:
Substances chimiques
Isocitrate Dehydrogenase
EC 1.1.1.41
Vimentin
0
HIP1R protein, human
0
Microfilament Proteins
0
Adaptor Proteins, Signal Transducing
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2121-2132Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Methods Mol Biol. 2018;1788:279-287
pubmed: 29071490
Brain Tumor Pathol. 2021 Oct;38(4):271-282
pubmed: 34338912
Acta Neuropathol. 2009 Nov;118(5):599-601
pubmed: 19798509
Nat Med. 2015 Apr;21(4):407-13
pubmed: 25730263
Acta Neuropathol. 2020 Oct;140(4):569-581
pubmed: 32776277
J Cell Biol. 1999 Dec 27;147(7):1503-18
pubmed: 10613908
Acta Neuropathol. 1998 May;95(5):493-504
pubmed: 9600596
Acta Neuropathol. 2018 Apr;135(4):639-642
pubmed: 29497819
Neurooncol Adv. 2020 Aug 27;2(1):vdaa109
pubmed: 33205043
J Neuropathol Exp Neurol. 2011 Nov;70(11):970-8
pubmed: 22002423
JCO Clin Cancer Inform. 2020 Oct;4:958-971
pubmed: 33119407
Acta Neuropathol. 2020 Mar;139(3):597-600
pubmed: 31912209
Acta Neuropathol. 2019 Aug;138(2):331-334
pubmed: 31065834
CNS Oncol. 2015;4(5):295-306
pubmed: 26545171
Mol Cancer. 2008 May 20;7:41
pubmed: 18492260
Acta Neuropathol. 2006 May;111(5):475-82
pubmed: 16598485
J Biol Chem. 2004 Apr 2;279(14):14294-306
pubmed: 14732715
Oncotarget. 2015 Oct 6;6(30):30295-305
pubmed: 26210286
Acta Neuropathol. 2008 Dec;116(6):597-602
pubmed: 18985363
Cancer Cell. 2003 May;3(5):471-82
pubmed: 12781365
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Acta Neuropathol. 2020 Jan;139(1):211-213
pubmed: 31773240
N Engl J Med. 2015 Jun 25;372(26):2499-508
pubmed: 26061753
Sci Rep. 2017 Sep 18;7(1):11741
pubmed: 28924174
Mol Cell Proteomics. 2018 Dec;17(12):2534-2545
pubmed: 30385480
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Neurology. 2009 Jan 13;72(2):156-61
pubmed: 19139367
Acta Neuropathol Commun. 2021 May 21;9(1):95
pubmed: 34020723
J Clin Pathol. 2011 Sep;64(9):793-801
pubmed: 21653654
Eur J Cancer. 2011 Mar;47(5):802-8
pubmed: 21194923
Acta Neuropathol. 2022 Feb;143(2):263-281
pubmed: 34967922
Neuro Oncol. 2010 Mar;12(3):243-56
pubmed: 20167812
Acta Neuropathol. 2015 Jan;129(1):133-46
pubmed: 25427834